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Glossary
Absorption-The transport of a chemical from the outer surface of the skin into both the skin and systemic circulation (including penetration, permeation, and resorption).
Acute exposure-Contact with a chemical that occurs once or for only a short period of time.
Cancer-Any one of a group of diseases that occurs when cells in the body become abnormal and grow or multiply out of control.
Contaminant-A chemical that is (1) unintentionally present within a neat substance or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen and present within a neat substance or mixture at a concentration less than 0.1%.
Cutaneous (or percutaneous)-Referring to the skin (or through the skin).
Dermal-Referring to the skin.
Dermal contact-Contact with (touching) the skin.
Direct effects-Localized, non-immune-mediated adverse health effects on the skin, including corrosion, primary irritation, changes in skin pigmentation, and reduction/disruption of the skin barrier integrity, occurring at or near the point of contact with chemicals.
Immune-mediated responses-Responses mediated by the immune system, including allergic responses.
Sensitization-A specific immune-mediated response that develops following exposure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis (ACD) or other immune-mediated diseases such as asthma, depending on the site and route of re-exposure. Substance-A chemical.
Systemic effects-Systemic toxicity associated with skin absorption of chemicals after exposure of the skin. 
Purpose
This skin notation profile presents (1) a brief summary of epidemiological and toxicological data associated with skin contact with morpholine and (2) the rationale behind the hazard-specific skin notation (SK) assignment for morpholine. The SK assignment is based on the scientific rationale and logic outlined in the Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009 ]. The summarized information and health hazard assessment are limited to an evaluation of the potential health effects of dermal exposure to morpholine. A literature search was conducted through February 2013 to identify information on morpholine, including but not limited to data relating to its toxicokinetics, acute toxicity, repeated-dose systemic toxicity, carcinogenicity, biological system/function-specific effects (including reproductive and developmental effects and immunotoxicity), irritation, and sensitization. Information was considered from studies of humans, animals, or appropriate modeling systems that are relevant to assessing the effects of dermal exposure to morpholine.
Overview of SK Assignment
Morpholine is potentially capable of causing numerous adverse health effects following skin contact. A critical review of available data has resulted in the following SK assignment for morpholine: SK: SYS-DIR (COR). Table 1 provides an overview of the critical effects and data used to develop the SK assignment for morpholine. 
Systemic Toxicity from Skin Exposure (SK: SYS)
No toxicokinetic data following dermal exposure to morpholine were identified. The potential of morpholine to pose a skin absorption hazard was also evaluated, with use of a predictive algorithm for estimating and evaluating the health hazards of dermal exposure to substances [NIOSH 2009 ]. The evaluation method compares an estimated dose accumulated in the body from skin absorption and an estimated dose from respiratory absorption associated with a reference occupational exposure limit. On the basis of this algorithm, a ratio of the skin dose to the inhalation dose (SI ratio) of 1.76 was calculated for morpholine. An SI ratio of ≥0.1 indicates that skin absorption may significantly contribute to the overall body burden of a substance [NIOSH 2009 ]; therefore, morpholine is considered to be absorbed through the skin following dermal exposure. Additional information on the SI ratio and the variables used in its calculation are included in the appendix.
No human dermal lethal dose (LD Lo ) estimates were identified. A minimum lethal dose of 0.9 grams per kilogram body weight [g/kg; 900 milligrams per kilogram body weight (mg/kg)] was reported in guinea pigs [Shea 1939 ]. The reported dermal LD 50 value (the dose resulting in 50% mortality in the exposed animals) was 0.5 milliliters per kilogram (mL/kg) [corresponding to 503.5 mg/kg] in the rabbit [Smyth et al. 1954] . Because the reported acute dermal LD 50 value for rats and the minimum lethal dose for guinea pigs were lower than the critical dermal LD 50 value of 2,000 mg/kg that identifies chemical substances with the potential for acute toxicity [NIOSH 2009 ], morpholine is considered acutely toxic following dermal exposure.
No epidemiological studies or human case reports or repeated-dose, sub-chronic, or chronic dermal toxicity studies in animals were identified. However, Shea [1939] reported a dermal toxicity study in rabbits and guinea pigs exposed to morpholine for up to 2 weeks to 900 mg/kg-day of diluted (aqueous) (rabbits) or undiluted (guinea pigs). In this study, all animals died before the eleventh (rabbits) or thirteenth (guinea pigs) dose. Morpholine at this dose caused necrosis of the liver and kidney tubules (rabbits and guinea pigs) and congestion of the spleen (rabbits). Although prolonged dermal exposure studies were not identified, the Shea [1939] study suggests the potential for effects at doses lower than the critical dermal No-Observed-Adverse-Effect-Level (NOAEL) value of 1000 mg/kg for repeat-dose toxicity that identifies chemical substances with the potential for repeated-dose dermal toxicity [NIOSH 2009] . Therefore, morpholine is considered to be systemically toxic, causing liver, kidney and spleen effects, following repeated dermal exposure. No standard toxicity or specialty studies were identified that evaluated biological system/function specific effects (including reproductive and developmental effects and immunotoxicity) following dermal exposure to morpholine. No studies were identified that evaluated the potential of morpholine to be a carcinogen in humans or animals following dermal exposure. Table 2 summarizes carcinogenic designations of multiple governmental and nongovernmental organizations for morpholine. Although no toxicokinetic data were identified to evaluate the potential of morpholine to be absorbed through the skin, data from acute dermal toxicity study in rabbits [Smyth et al. 1954] 1 and a short-term dermal toxicity study in guinea pigs and rabbits [Shea 1939 ] are sufficient to suggest that that morpholine can be absorbed by the skin, systemically available, and toxic, with the potential to cause liver, kidney and spleen effects following repeated exposure. Therefore, on the basis of the data for this assessment, morpholine is assigned the SK: SYS notation.
Direct Effects on Skin (SK: DIR)
Only one study was identified that reported the potential of morpholine to have direct effects on human skin. Shea [1939] reported that undiluted morpholine applied to the human fingertip caused cracking of the cuticle and epithelium of the nail bed and burning sensations. Evidence of skin corrosivity of morpholine is well-documented in experimental animals. Occluded topical application of 900 mg/kg of the undiluted or un-neutralized morpholine as a single dose or same dose of diluted morpholine applied daily for up to two weeks caused necrosis of the skin, inflammation, edema, and severe burning in rabbits [Shea 1939 ]. Guinea pigs receiving occluded, daily topical application of 900 mg/kg undiluted morpholine for up two weeks also exhibited edema and necrosis of the skin [Shea 1939 ]. Smyth [1954] 4
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reported that topical application of 0.001 mL of undiluted morpholine [corresponding to 1 mg] resulted in skin necrosis in rabbits within 24 hours. Wang and Suskind [1988] reported 0.1 g applications of 0.5, 2, 5 and 10% morpholine concentrations produced no irritation when applied to 1.5 squared centimeter (cm 2 ) of the shaved skin of guinea pigs under occlusive conditions.
Evidence of direct skin effects of morpholine in humans and animals are also provided by in vitro studies. Gay et al. [1992] applied morpholine to living skin equivalent (LSE), collagen-fibroblast lattice from which human epidermal keratinocytes forms a stratified epidermis. Concentrations greater than 1% morpholine (by weight) were required to produce inflammation, indicative of irritation in both rabbit and human LSE. In a similar study conducted by van de Sandt and Rutten [1995] , rabbit cell cultures administered 5% morpholine solution exhibited no changes. The structure-activity relationship model, Deductive Estimation of Risk from Existing Knowledge (DEREK) for Windows, predicted morpholine to be negative for skin irritation.
Based on the results of the studies that evaluated the direct effects of undiluted morpholine in animals [Shea 1939; Smyth 1954] , there is sufficient information that suggests that morpholine is corrosive to the skin. Therefore, on the basis of the data for this assessment, morpholine is assigned the SK: DIR (COR) notation.
Immune-mediated Responses (SK: SEN)
No evidence was identified in human studies to suggest that morpholine has the potential to produce skin sensitization. Animal data was limited to a single study. In a modified Buehler test [Wang and Suskind 1988] , 10 guinea pigs were administered 0.1 g morpholine in 5% petrolatum under occlusion on clipped napes for 1 hour for 3 days/week for 2 weeks. Two weeks after the final dose, the guinea pigs were challenged with 0.1, 0.5, and 2 % morpholine concentrations, and no sensitization was observed; however, Wang and Suskind [1988] reported cross-sensitization reactions when animals were initially sensitized with 4,4-dithiodimorpholine (DTDM) or morpholinyl-mercaptobenzothiazole (MMBT) and then challenged with morpholine. The structure activity relationship model, DEREK for Windows, predicted morpholine to be negative for skin sensitization.
The modified Buehler test identified suggests that morpholine is not a skin sensitizer, but can cross-react with structurally similar chemicals. However, this information is considered insufficient as the basis for assigning a SK-SYS notation for morpholine. Therefore, on the basis of the data for this assessment, morpholine is not assigned the SK: SEN notation.
Summary
No toxicokinetic data were identified to evaluate the potential of morpholine to be absorbed through the skin. However, data from acute dermal toxicity study in rabbits [Smyth et al. 1954 ] and a short-term dermal toxicity study in guinea pigs and rabbits [Shea 1939 ] are sufficient to indicate that morpholine has the potential to be absorbed through the skin, be systemically available and toxic, with the potential to cause liver, kidney and spleen effects following repeated exposure. indicate that undiluted morpholine is corrosive to the skin [Shea 1939; Smyth 1954] . Results from a modified Buehler test suggest that morpholine is not likely to cause skin sensitization, but can crossreact with structurally similar chemicals. Therefore, on the basis of these assessments, morpholine is assigned a composite skin notation of SK: SYS-DIR (COR). Table 3 summarizes the skin hazard designations for morpholine previously issued by NIOSH and other organizations. The equivalent dermal designation for morpholine, according to the Global Harmonization System (GHS) of Classification and Labelling of Chemicals, is Acute Toxicity Category 4 (Harmful in contact with the skin) and Skin Corrosion Category 1B (Causes severe skin burns and eye damage) [European Parliament 2008] . 
Appendix: Calculation of the SI Ratio for Morpholine
This appendix presents an overview of the SI ratio and a summary of the calculation of the SI ratio for morpholine. Although the SI ratio is considered in the determination of a substance's hazard potential following skin contact, it is intended only to serve as supportive data during the assignment of the NIOSH SK. An in-depth discussion on the rationale and calculation of the SI ratio can be found in Appendix B of the Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009 ].
Overview
The SI ratio is a predictive algorithm for estimating and evaluating the health hazards of skin exposure to substances. The algorithm is designed to evaluate the potential for a substance to penetrate the skin and induce systemic toxicity [NIOSH 2009 ]. The goals for incorporating this algorithm into the proposed strategy for assigning SYS notation are as follows:
(1) Provide an alternative method to evaluate substances for which no clinical reports or animal toxicity studies exist or for which empirical data are insufficient to determine systemic effects. (2) Use the algorithm evaluation results to determine whether a substance poses a skin absorption hazard and should be labeled with the SYS notation.
The algorithm evaluation includes three steps:
(1) determining a skin permeation coefficient (k p ) for the substance of interest, (2) estimating substance uptake by the skin and respiratory absorption routes, and (3) evaluating whether the substance poses a skin exposure hazard.
The algorithm is flexible in the data requirement and can operate entirely on the basis of the physicochemical properties of a substance and the relevant exposure parameters. Thus, the algorithm is independent of the need for biologic data. Alternatively, it can function with both the physicochemical properties and the experimentally determined permeation coefficient when such data are available and appropriate for use.
The first step in the evaluation is to determine the k p for the substance to describe the transdermal penetration rate of the substance [NIOSH 2009 ]. The k p , which represents the overall diffusion of the substance through the stratum corneum and into the blood capillaries of the dermis, is estimated from the compound's molecular weight (MW) and base-10 logarithm of its octanol-water partition coefficient (log KOW). In this example, k p is determined for a substance with use of Equation 1. A self-consistent set of units must be used, such as centimeters per hour (cm/hr), outlined in The second step is to calculate the biologic mass uptake of the substance from skin absorption (skin dose) and inhalation (inhalation dose) during the same period of exposure. The skin dose is calculated as a mathematical product of the kp, the water solubility (SW) of the substance, the exposed skin surface area, and the duration of exposure. Its units are milligrams (mg). Assume that the skin exposure continues for 8 hours to unprotected skin on the palms of both hands (a surface area of 360 squared centimeters [cm 2 ]).
Equation 2: Determination of Skin Dose
Skin dose = k p × S w × Exposed skin surface area × Exposure time = k p (cm/hr) × S w (mg/cm 3 ) × 360 cm 2 × 8 hr
The inhalation dose (in mg) is derived on the basis of the occupational exposure limit (OEL) of the substance-if the OEL is developed to prevent the occurrence of systemic effects rather than sensory/irritant effects or direct effects on the respiratory tract. Assume a continuous exposure of 8 hours, an inhalation volume of 10 cubic meters (m 3 ) inhaled air in 8 hours, and a factor of 75% for retention of the airborne substance in the lungs during respiration (retention factor, or RF). The final step is to compare the calculated skin and inhalation doses and to present the result as a ratio of skin dose to inhalation dose (the SI ratio). This ratio quantitatively indicates (1) the significance of dermal absorption as a route of occupational exposure to the substance and (2) the contribution of dermal uptake to systemic toxicity. If a substance has an SI ratio greater than or equal to 0.1, it is considered a skin absorption hazard. Table A1 summarizes the data applied in the previously described equations to determine the SI ratio for morpholine. The calculated SI ratio was 1.76. On the basis of these results, morpholine is predicted to represent a skin absorption hazard. The OEL used in calculation of the SI ratio for morpholine was the NIOSH recommended exposure limit (REL) [NIOSH 2005 ].
Calculation

